Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.79 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | GC | P02774 | 1/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
| ▸ | RXRA | P19793 | 1/20 | 0.79 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | HTR2C | P28335 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.79 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maxacalcitol SCHEMBL5617040 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL14490724 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL5153677 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL25095406 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL17975926 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL24066887 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL4893368 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL20461177 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL7203090 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL3189866 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111447-A1 | TREATMENT OF CANCER WITH DRUG COMBINATIONS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2024-11-14 | — | — | US | claimed |
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | claimed |
| CN-118215496-A | Immunomodulatory combinations of antigens and drug-lipid conjugates | 集成纳米治疗股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| US-20230398130-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-14 | — | — | US | claimed |
| EP-4232012-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | Massachusetts Institute of Technology (US) | 2023-08-30 | — | — | EP | claimed |
| EP-3112476-B1 | METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS | EIRGEN PHARMA LTD (IE) | 2023-08-02 | — | — | EP | claimed |
| WO-2023035068-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2023-03-16 | — | — | WO | claimed |
| WO-2022087526-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-04-28 | — | — | WO | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| US-6248732-B1 | ADMINISTERING MIXTURE OF ACTIVATED VITAMIN D AND VITAMIN C TO EYE TO TREAT POST OPHTHALMIC SURGERY TISSUE DETERIORATION | KATSUHIKO MUKAI (JP) | 2001-06-19 | — | — | US | claimed |
| US-6187331-B1 | Composition for prophylaxis and/or treatment of dry syndrome comprising vitamin D | NEW VISION CO., LTD. (JP) | 2001-02-13 | — | — | US | claimed |
| EP-1059085-A1 | LANGERHANS CELL MIGRATION INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-12-13 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061604-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| EP-0998925-A1 | MEDICINAL COMPOSITIONS FOR TOPICAL ADMINISTRATION CONTAINING VITAMIN D AND VITAMIN K | New Vision Co., Ltd. (JP) | 2000-05-10 | — | — | EP | claimed |
| EP-0992242-A1 | VITAMIN D-CONTAINING PREVENTIVES AND/OR REMEDIES FOR CONJUNCTIVAL/CORNEAL XEROSIS | New Vision Co., Ltd. (JP) | 2000-04-12 | — | — | EP | claimed |
| US-5876709-A | Ophthalmic composition containing active Vitamin D | NEW VISION CO., LTD. (JP) | 1999-03-02 | — | — | US | claimed |
| EP-0815862-A1 | OPHTHALMOLOGICAL COMPOSITION COMPRISING ACTIVATED VITAMIN D | Mukai, Katsuhiko (JP) | 1998-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | LY96, CD74, TLR9 | VDR 671/4885MAPT 3671/4885ADORA3 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.